Imunon, Inc. IMNN 深 滬
已收盤 04-02 16:00:00 美东时间
3.22
+0.230
+7.69%
華盛通- 最 高3.24
- 今 開2.93
- 成交量 3.76万股
- 最 低 2.85
- 昨 收 2.99
- 總市值 1094.91万
- 52周最高 41.2174
- 市盈率 靜 --
- 換手率 1.11%
- 52周最低 2.52
- 委 比 -89.65%
- 總股本 340.04万
- 歷史最高 25857.3851
- 量 比 0.62
- 振 幅 13.04%
- 歷史最低 2.52
- 每 手 1
- 風險率 5.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(1.13) by 15.04 percent. This is a 56.67 percent increase over losses of $(3.00) per share from the same
03-31 20:12
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
Watching Imunon; Zacks Small-Cap Research Gives Stock $33 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03252026_IMNN_Bautz.pdf
03-25 23:11
IMUNON Reports Improved Survival In OVATION 2 Trial, With IMNN-001 Extending Overall Survival Up To 24.2 Months
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysisPatients treated with PARP
03-25 20:08
IMUNON Announces $7M Registered Direct Offering Of 1.94M Shares And Warrants Priced At A Combined Price Of $3.61
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused
2025-12-30 21:32
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Imunon (NASDAQ:IMNN) shares increased by 8.8% to $3.6 during Wednesday...
2025-12-25 05:05
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
IMUNON Updates on Final Phase 3 Trial for its DNA-Based Ovarian Cancer Therapy
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today is presenting an update on recent progress with its IMNN-001 development program for the treatment of
2025-11-10 20:44
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
IMUNON, Inc. is advancing its IMNN-001 therapy for advanced ovarian cancer, with new Phase 2 data to be presented at SITC 2025. The IL-12 DNA-based therapy shows improved survival and immune response in trials. The pivotal Phase 3 OVATION 3 trial is ongoing to confirm these results.
2025-10-23 14:01
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
IMUNON Inc. will host an R&D Day for investors on November 10, 2025, in New York City, to provide updates on its Phase 3 study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. Keynote speakers include ovarian cancer experts, principal investigators, and statistical experts, who will discuss the latest data and progress of the OVATION 3 Study. The event will also feature a live Q&A session and networking opportunities. IMUNON...
2025-10-20 12:05
